中木國際(01822.HK):上市複核委員會維持決定 10月22日起停牌
格隆匯10月22日丨中木國際(01822.HK)發佈公吿,上市復核委員會復核已於2021年9月28日舉行。2021年10月21日,公司接獲聯交所通知公司的函件,內容有關聯交所上市復核委員會經考慮公司及聯交所上市科所提交的全部資料(包括書面及口頭資料)後,決定維持該決定,根據上市規則第6.01(3)條暫停公司股份買賣。上市復核委員會認為,於複核聆訊當時,公司未能向上市復核委員會充分證明,令其信納公司維持有上市規則第13.24條所要求的足夠業務運作水平及足以支持營運的相當價值資產,以保證股份繼續上市。公司股份已自2021年10月22日上午九時正起於聯交所暫停買賣,並將繼續暫停直至進一步通知止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.